Latest Singular Health (ASX:SHG) News

Singular Health has signed a non-binding MOU to build and operate a medical imaging repository for Florida Medicaid, with approximately A$3.5 million of potential revenue subject to definitive agreements and delivery. The project could give its 3DICOM platform a state-funded infrastructure reference site, but recurring funding remains unassured.

Singular Health Group lifted revenues over fivefold to $1.43 million in FY26, driven by US commercial rollouts of its 3DICOM platform, but posted a $6.34 million loss. The company strengthened its US foothold with FDA clearance and a controlling stake in an associate.

Singular Health deepens US healthcare foothold with ongoing Triple-S contract talks, PNS licence expansion, and Miami-Dade educational rollout, supported by a solid $10.1 million cash reserve.

Singular Health boosted its US presence by deploying 500 additional 3DICOM MD® licenses to Provider Network Solutions, securing FDA 510(k) clearance for its cloud platform, and launching education pilots with Miami-Dade schools and Florida International University.

Singular Health has received a US$500,000 payment from Provider Network Solutions following the deployment of an additional 500 3DICOM MD® licenses, marking progress in commercial adoption and cost-saving benefits within a major US healthcare network.

Small caps stole the week, led by a big funding deal in gold and two revenue breakouts. Meanwhile, some well-known names slid after profit updates failed to calm nerves on costs and outlooks.

Cannabis and psychedelics delivered the week’s biggest winner, while a cluster of smaller caps slid on fresh losses, leadership change, and near-term uncertainty. Investors kept paying up for FDA clearances and reimbursement wins, but punished businesses where early pops quickly disappeared.

Singular Health Group reported a 55% rise in net loss to $2.97 million for H1 FY2026, driven by share-based payments and strategic hires, while making significant progress in US commercial deployments and securing FDA clearance for its cloud-based 3D medical imaging platform.

A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.

Singular Health Group has advanced its U.S. commercial footprint with the deployment of 500 new licences under its PNS contract and secured FDA clearance for its cloud-based 3DICOM MD® platform, positioning the company for significant growth.

Singular Health has submitted a 510(k) premarket notification to the FDA for its enhanced 3DICOM MD Cloud platform, aiming to expand imaging capabilities and introduce a scalable, cloud-native solution for medical image management.

Singular Health Group has advanced its US expansion through the deployment of 3DICOM™ licenses under a key contract with Provider Network Solutions, alongside appointing a new US commercial chief to drive growth.